These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27848167)

  • 21. Bendamustine-PAMAM Conjugates for Improved Apoptosis, Efficacy, and in Vivo Pharmacokinetics: A Sustainable Delivery Tactic.
    Gothwal A; Khan I; Kumar P; Raza K; Kaul A; Mishra AK; Gupta U
    Mol Pharm; 2018 Jun; 15(6):2084-2097. PubMed ID: 29195048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
    Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
    J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
    Han L; Huang R; Liu S; Huang S; Jiang C
    Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methotrexate Nanoparticles Prepared with Codendrimer from Polyamidoamine (PAMAM) and Oligoethylene Glycols (OEG) Dendrons: Antitumor Efficacy in Vitro and in Vivo.
    Zhao Y; Guo Y; Li R; Wang T; Han M; Zhu C; Wang X
    Sci Rep; 2016 Jul; 6():28983. PubMed ID: 27388443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
    Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
    Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.
    Huang S; Li J; Han L; Liu S; Ma H; Huang R; Jiang C
    Biomaterials; 2011 Oct; 32(28):6832-8. PubMed ID: 21700333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
    Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
    J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for intracellular delivery of doxorubicin.
    Hu W; Qiu L; Cheng L; Hu Q; Liu Y; Hu Z; Chen D; Cheng L
    Acta Biomater; 2016 May; 36():241-53. PubMed ID: 26995505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
    Li Y; He H; Jia X; Lu WL; Lou J; Wei Y
    Biomaterials; 2012 May; 33(15):3899-908. PubMed ID: 22364698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
    Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
    Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
    Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
    Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
    Huo M; Zou A; Yao C; Zhang Y; Zhou J; Wang J; Zhu Q; Li J; Zhang Q
    Biomaterials; 2012 Sep; 33(27):6393-407. PubMed ID: 22704599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
    Jiang G; Li R; Tang J; Ma Y; Hou X; Yang C; Guo W; Xin Y; Liu Y
    Oncol Rep; 2017 Feb; 37(2):995-1001. PubMed ID: 28035395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates.
    Zhang Y; Sun Y; Xu X; Zhang X; Zhu H; Huang L; Qi Y; Shen YM
    J Med Chem; 2010 Apr; 53(8):3262-72. PubMed ID: 20350006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEGylated PAMAM dendrimer-doxorubicin conjugate-hybridized gold nanorod for combined photothermal-chemotherapy.
    Li X; Takashima M; Yuba E; Harada A; Kono K
    Biomaterials; 2014 Aug; 35(24):6576-84. PubMed ID: 24816361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.
    Wang K; Zhang X; Zhang L; Qian L; Liu C; Zheng J; Jiang Y
    Drug Deliv; 2015 May; 22(3):389-99. PubMed ID: 24670095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors.
    He H; Li Y; Jia XR; Du J; Ying X; Lu WL; Lou JN; Wei Y
    Biomaterials; 2011 Jan; 32(2):478-87. PubMed ID: 20934215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
    Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
    Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sugar Modification Enhances Cytotoxic Activity of PAMAM-Doxorubicin Conjugate in Glucose-Deprived MCF-7 Cells - Possible Role of GLUT1 Transporter.
    Sztandera K; Działak P; Marcinkowska M; Stańczyk M; Gorzkiewicz M; Janaszewska A; Klajnert-Maculewicz B
    Pharm Res; 2019 Jul; 36(10):140. PubMed ID: 31367876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent.
    Han L; Li J; Huang S; Huang R; Liu S; Hu X; Yi P; Shan D; Wang X; Lei H; Jiang C
    Biomaterials; 2011 Apr; 32(11):2989-98. PubMed ID: 21277017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.